ScholarLens Back to search
2008•Biochemical PharmacologyRequires access

DPP4 inhibitors for diabetes—What next?

Anne‐Marie Lambeir, Simon Scharpé, Ingrid De Meester

Open publisher page 58 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 58 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Vildagliptin, Sitagliptin, Dipeptidyl peptidase-4, Diabetes mellitus, Dipeptidyl peptidase, Medicine, Pharmacology, Type 2 diabetes

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
DPP4 inhibitors for diabetes—What next? — Research Paper | ScholarLens